Summary: Wave Life Sciences Announces Success in First-Ever Human RNA Editing Clinical Trial, Marking a Critical Milestone in Precision Medicine”
Summary: GlycoMimetics, following unsuccessful Phase 2/3 clinical trials, accepted the transaction allocating 3.1% equity in the post-merger entity to its shareholders.
Summary: The acquisition provided Lundbeck with rights to vexicaserin, an investigational therapy targeting 5-HT2C receptors involved in seizure severity modulation.
Summary: After forming a gene therapy partnership with Dyno Therapeutics in 2020, they announced a $50 million upfront payment to design new adeno-associated virus (AAV) vectors as gene therapy delivery tools.
Summary: Novartis Faces Setback in Acquisition Strategy. Months post-acquisition, the company disclosed safety concerns that may result in multi-year delays for the core asset’s approval submission.
